(Oslo, 03.02.2015) Bionor Pharma ASA announces that the Company has received a waiver under the Public Limited Liability Companies Act section 6-11 for the appointment of David Solomon as CEO.
The PLLCA section 6-11 requires a CEO to be a Norwegian or EEA citizen. Dr. Solomon who was appointed as new CEO of Bionor Pharma 9 January 2015 is Canadian/US citizen.
Bionor Pharma ASA
Synne H. Røine, CFO
+47 99 22 98 92
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.